Beovu shows Real-World promise for two common eye diseases
NCT ID NCT04543331
First seen Jan 02, 2026 · Last updated May 16, 2026 · Updated 12 times
Summary
This study looked at how well the eye medication Beovu (brolucizumab) works in everyday medical practice for people with wet age-related macular degeneration (AMD) or diabetic macular edema (DME). Researchers observed 572 patients who were already prescribed Beovu by their doctor, tracking fluid buildup in the eye and changes in vision over time. The goal was to see if the drug's benefits seen in clinical trials hold up in real life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Munich, Bavaria, 81377, Germany
-
Novartis Investigative Site
Würzburg, Bavaria, 97070, Germany
-
Novartis Investigative Site
Würzburg, Bavaria, 97080, Germany
-
Novartis Investigative Site
Frankfurt am Main, Hesse, 60590, Germany
-
Novartis Investigative Site
Göttingen, Lower Saxony, 37075, Germany
-
Novartis Investigative Site
Osnabrück, Lower Saxony, 49076, Germany
-
Novartis Investigative Site
Rostock, Mecklenburg-Vorpommern, 18057, Germany
-
Novartis Investigative Site
Trier, Rhineland-Palatinate, 54296, Germany
-
Novartis Investigative Site
Dresden, Saxony, 01307, Germany
-
Novartis Investigative Site
Leipzig, Saxony, 04103, Germany
-
Novartis Investigative Site
Schneeberg, Saxony, 08289, Germany
-
Novartis Investigative Site
Halle, Saxony-Anhalt, 06118, Germany
-
Novartis Investigative Site
Jena, Thuringia, 07740, Germany
-
Novartis Investigative Site
Aschersleben, 06449, Germany
-
Novartis Investigative Site
Bayreuth, 95445, Germany
-
Novartis Investigative Site
Berlin, 10713, Germany
-
Novartis Investigative Site
Berlin, 14163, Germany
-
Novartis Investigative Site
Bonn, 53105, Germany
-
Novartis Investigative Site
Breisach, 79206, Germany
-
Novartis Investigative Site
Chemnitz, 09113, Germany
-
Novartis Investigative Site
Cologne, 50968, Germany
-
Novartis Investigative Site
Dresden, 01067, Germany
-
Novartis Investigative Site
Dresden, 01324, Germany
-
Novartis Investigative Site
Esslingen am Neckar, 73728, Germany
-
Novartis Investigative Site
Glauchau, 08371, Germany
-
Novartis Investigative Site
Homburg, 66421, Germany
-
Novartis Investigative Site
Hösbach, 63768, Germany
-
Novartis Investigative Site
Kiel, 24103, Germany
-
Novartis Investigative Site
Leipzig, 04106, Germany
-
Novartis Investigative Site
Magdeburg, 39104, Germany
-
Novartis Investigative Site
Marienberg, 09496, Germany
-
Novartis Investigative Site
Münster, 48145, Germany
-
Novartis Investigative Site
Neubrandenburg, 17036, Germany
-
Novartis Investigative Site
Neuburg am Inn, 86633, Germany
-
Novartis Investigative Site
Saarbrücken, 66111, Germany
-
Novartis Investigative Site
Schönebeck, 39218, Germany
-
Novartis Investigative Site
Stralsund, 18435, Germany
-
Novartis Investigative Site
Sulzbach, 66280, Germany
-
Novartis Investigative Site
Torgau, 04860, Germany
-
Novartis Investigative Site
Waren, 17192, Germany
-
Novartis Investigative Site
Würzburg, 97080, Germany
Conditions
Explore the condition pages connected to this study.